-
Mashup Score: 16Mayo Clinic Cardiovascular Education - 3 day(s) ago
Mayo Clinic is committed to taking care of our patients, learners and staff. Mayo Clinic Department of Cardiovascular Medicine education is actively planning livestream courses, webinars, and other virtual learning opportunities. We continue to closely monitor future in-person meetings as the CDC makes further recommendations. We’re happy to answer any questions you might have. Give us a call or send us an email and we’ll get back to you shortly. © 2025 Mayo Foundation for Medical Education and Research.
Source: cveducation.mayo.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 47
177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant 177Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials. Methods: In this investigator-initiated, parallel-group, open-label, phase 2 trial, patients with grade 1/2 GEP-NETs, having progressive somatostatin receptor–positive, locally advanced, or metastatic disease on 68Ga-DOTANOC PET/CT, were randomly assigned in a 1:1 ratio to 177Lu-DOTATATE plus capecitabine (experimental arm) or 177Lu-DOTATATE only (control arm). 177Lu-DOTATATE was administered at approximately 7.4 GBq/cycle intravenously, for up to 4 cycles, at 8 wk intervals, whereas capecitabine was given at 1,250 mg/m2/d orally from day 0 to day 14 of each cycle of 177Lu-DOTATATE. The primary endpoint was the
Source: jnm.snmjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Does radiosensitizing capecitabine improve the efficacy of PRRT in progressive GEPNETs...? This small phase II RCT does not suggest so and I remain thoroughly unconvinced that adding chemo to PRRT does anything beneficial. Big kudos to this team! https://t.co/w6VCk0lS9X
-
-
Mashup Score: 22Page Expired - 3 day(s) ago
The page you are trying to access is no longer available. Please close the tab and open a new product Login
Source: login.wolterskluwer.comCategories: General Medicine News, Hem/OncsTweet-
Cystic panc NETs seem to have better prognosis than solid pNETs. Certainly not new info but by far the largest study I have seen and very clinically relevant. Can we observe localized cystic pNETs 3 cm and smaller...? https://t.co/B7p92v31C1 https://t.co/SaOOFmWrKg
-
-
Mashup Score: 10
Abstract. Background: Neuroendocrine neoplasias grade 3 (NEN G3) are rare tumors with poor prognosis and no established second-line therapy. The role of immune checkpoint blockade in these aggressive tumors remains unclear. Methods: The phase II AVENEC study evaluated the effect of avelumab (AVE, 10 mg/kg IV Q2W) in 60 patients with well-differentiated high-grade neuroendocrine tumors (NET G3, N=22) or poorly differentiated neuroendocrine carcinomas (NEC, N=38) progressing after ≥ one prior chemotherapy (excluding Merkel cell and small-cell lung cancer). Results: The best overall response according to iRECIST was partial response (PR) in 3 (5%) and stable disease (SD) in 9 (15%) patients, with a disease control rate at 16 weeks of 15% (3 PR, 6 SD), and a median duration of response of 4.3 months. Six patients (10%) achieved SD or PR for > 6 months and two for > one year. Response rates were similar regardless of differentiation, Ki67 expression, or primary localization. The median prog
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Avelumab in high-grade NETs and NECs. Although some stability was observed, the ORR was only 5% and the PFS 1.9 months. In line with other single-agent ICI trials in NECs. Hard to interpret this as a real clinical benefit if you ask me... Unimpressive... https://t.co/vd87iqDt5a
-
-
Mashup Score: 25Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients | JCO Precision Oncology - 5 day(s) ago
PURPOSEBiliary tract cancers (BTCs) include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancers. BTCs have a number of genomic alterations, including isocitrate dehydrogenase 1 (IDH1) mutations, fibroblast …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Need info on the rare acinar cell carcinoma of the pancreas (PACC)? 48% with resectable tumors and 5-yr OS following resection was 72% Outcomes of pts w/ metastatic and unresectable PACC are poor, 5-yr OS of 21%, seemingly better than PDAC. https://t.co/k3UKoiztbZ https://t.co/3fYgvtBmYQ
-
-
Mashup Score: 9
The study did not say why coffee in the morning reduces the risk and whether it was the sole cause.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet-
Sometimes I feel like I only need to read the headline... 😄 https://t.co/pGsKmtbH8w
-
-
Mashup Score: 1Daily Cartoon: Friday, January 3rd - 9 day(s) ago
“Do you have any nonalcoholic options?”
Source: www.newyorker.comCategories: General Medicine News, Hem/OncsTweet-
Listen to the Surgeon General… https://t.co/cOBMIb8UFQ https://t.co/OTGkjfBX0q
-
-
Mashup Score: 49
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Categories: General Medicine News, Hem/OncsTweet-
What's new in the 9th AJCC version of staging of gastroenteropancreatic NETs (GEPNETs)? Read all about it here. There have been some changes... @AmanChauhanMD @IHC_guy @adasarimd @thomashopemd @TubaKendi @DanielAnayaMD @ErikMittraMD https://t.co/TMeR6ITDse
-
-
Mashup Score: 1Cindy Lee: Diamond Jubilee - 14 day(s) ago
Read Andy Cush’s review of the album.
Source: pitchfork.comCategories: General Medicine News, Hem/OncsTweet-
Hands down the best album of 2024 and this was a good year in music. Stolen from NYT: “Diamond Jubilee” plays out like one long, late-night transmission from a pirate radio station that can only be heard when an antenna is pointed just so” https://t.co/3cckI3KJTP
-
-
Mashup Score: 18
PurposeData that guide selection of optimal local ablative therapy for the management localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective comparative data for these treatment modalities, we aimed to compare the …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
And this is why we do randomized, controlled trials, my friends... You work with the data you have at the time until you get better quality data. I like being proven wrong, especially if based on solid data (see below)... 😀 https://t.co/mcoFhaLfVK https://t.co/hJ2WEfNxk3
-
Want to know more about carcinoid heart disease (CHD)? If so, you might find this webinar by members the Mayo CHD team informative. Dr's. Juan Crestanello (Cardiothoracic Surgery), S. Allen Luis (Cardiology) and then an oncologist... https://t.co/r5M9GbHdWq